Rare ERBB4 variants are infrequently observed among ALS patients, and most missense variants in ERBB4 are likely non-pathogenic, yet the NRG1-ERBB4 axis holds significant potential for monitoring ALS progression and serving as a therapeutic target. Here, ERBB4 is linked to amyotrophic lateral sclerosis.